Copyright
©The Author(s) 2016.
World J Hepatol. Dec 28, 2016; 8(36): 1623-1628
Published online Dec 28, 2016. doi: 10.4254/wjh.v8.i36.1623
Published online Dec 28, 2016. doi: 10.4254/wjh.v8.i36.1623
Subject number | Gender | Age (yr) | Ethnicity | Prior DDI exposure (mo) | Time since DDI (yr) | BMI (kg/m2) | MAST score | ALT (IU/mL) | PLTs (106/L) | PTT | Alk Phos (U/L) | FS (kPa) | Ultrasound results | Biopsy results | HVPG | Fib 4 |
Participants who accepted to undergo TJLB as a result of study screening | ||||||||||||||||
1 | Male | 43 | White British | 81 | 7 | 25.58 | 0 | 77 | 175 | 14.0 | 83 | 10 | Splenomegaly | NRH with mild steatosis | 5 | 1.29 |
2 | Male | 59 | White British | 40 | 6 | 24.42 | 0 | 36 | 175 | 14.8 | 93 | 8 | Normal | NRH | 4 | 2.39 |
3 | Male | 48 | White British | 9 | 6 | 29.76 | 0 | 32 | 184 | 14.3 | 108 | NR | Fatty liver, Splenomegaly | Moderate steatosis | 3 | 1.08 |
4 | Male | 52 | White British | 70 | 7 | 24.69 | 0 | 50 | 242 | 11.7 | 44 | 5.6 | Fatty liver | Mild steatosis | 3 | 0.79 |
5 | Male | 49 | White Other | 34 | 4 | 28.54 | 1 | 60 | 215 | 14.0 | 83 | 12.6 | Fatty liver | Moderate steatosis, moderate fibrosis | 3 | 1.38 |
6 | Male | 52 | White British | 21 | 11 | 28.67 | 1 | 58 | 257 | 13.4 | 43 | NR | Fatty liver | Moderate steatosis | Not done | 1.02 |
7 | Male | 62 | White Other | 13 | 13 | 32.56 | 2 | 56 | 175 | 11.1 | 45 | NR | Fatty liver | Moderate steatosis | 2 | 2.25 |
8 | Male | 50 | White British | 117 | 3 | 31.18 | 0 | 125 | 204 | 10.7 | 58 | 8.7 | Fatty liver | Mild fibrosis with mild steatosis | 2 | 1.71 |
9 | Female | 56 | Black African | 24 | 11 | 36.96 | 0 | 27 | 208 | 12.3 | 67 | 4.4 | Coarse echotexture | Normal Architecture | 5 | 1.07 |
10 | Male | 57 | White British | 61 | 4 | 0 | 40 | 190 | 13.9 | 71 | NR | Splenomegaly | Normal Architecture | 3 | 1.74 | |
11 | Male | 51 | White Irish | 103 | 4 | 20.30 | 0 | 56 | 228 | 10.8 | 154 | 4.8 | Coarse echotexture | Normal Architecture | 3 | 1.04 |
12 | Male | 52 | White Other | 44 | 5 | 21.07 | 6 | 24 | 224 | 11.4 | 62 | 9.1 | Normal | Normal Architecture | 2 | 1.16 |
Participants who refused TJLB offered as a result of study screening | ||||||||||||||||
13 | Male | 46 | White British | 74 | 2 | 21.46 | 0 | 18 | 177 | 60 | 10 | Normal | Declined | 1.41 | ||
14 | Male | 41 | White British | 97 | 3 | 25.65 | 0 | 63 | 188 | 101 | 7.6 | Splenomegaly | Declined | 1.30 | ||
15 | Male | 47 | White British | 33 | 5 | 24.39 | 0 | 34 | 238 | 58 | 7.1 | Fatty liver, dampened waveform | Declined | 0.99 | ||
16 | Male | 61 | White British | 110 | 2 | 20.75 | 1 | 35 | 246 | 71 | 9.2 | Normal | Declined | 1.39 | ||
17 | Male | 54 | White British | 28 | 5 | 28.93 | 1 | 32 | 333 | 58 | 4.3 | Fatty liver | Declined | 0.67 |
- Citation: Logan S, Rodger A, Maynard-Smith L, O’Beirne J, Fernandez T, Ferro F, Smith C, Bhagani S. Prevalence of significant liver disease in human immunodeficiency virus-infected patients exposed to Didanosine: A cross sectional study. World J Hepatol 2016; 8(36): 1623-1628
- URL: https://www.wjgnet.com/1948-5182/full/v8/i36/1623.htm
- DOI: https://dx.doi.org/10.4254/wjh.v8.i36.1623